Acetonitrile, 51
Acquired Immune Deficiency Syndrome (AIDS), 5,13, 50
Acquired immunity, 4-5,17-18
Adaptive immunity. See Acquired immunity
Aflatoxin, 53
Agency for Toxic Substances and Disease Registry (ATSDR)
    meeting on human exposure data sponsored by, 32
    information programs of, 61,63
    research by, 9,49,53
Airborne pollutants
    EPA studies on, 52
    immunosuppression and, 7,37
Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), research by, 8,53
Aldicarb oxime, 51
Alkylating agents, 35
Allergy
    definition used in OTA background paper, 4,19,20
    disability claims and, 69
    genetic component of, 22
    misperceptions about, 22
    substances that induce, 38-39
    see also Contact sensitivity; Delayed-type hypersensitivity; Hypersensitivity; Immediate-type hypersensitivity
Allyl isovalerate, 51
American Academy of Allergy and Immunology, 76
American Conference of Governmental Industrial Hygienists (ACGIH), 54,61
Anaphylaxis. See Immediate-type hypersensitivity; Hypersensitivity; Allergy
Antibody
    classes of (immunoglobulin), 14
    humoral immunity and, 18-19
    plaque forming cell response test, 28
    production by B cells of, 4,14
    role in immune responsiveness of, 4, 14-15
    structure, 14
    test to measure levels of, 5,29
Antigen
    acquired immunity and, 17
    binding to antibody of, 13-14
    definition of, 4,13
    humoral immunity and, 18-19
    processing of, 16
    self, 20
Antimetabolites, 35
Arsine, 51
Asthma, 8,22,39,69
Autoimmune disease. See Autoimmunity
Autoimmunity
    as a response of the immune system, 4,20
    difficulty in assessing, 20,40
    disability claims and, 69
    epidemiologic studies of humans for, 6,40
    genetic role in, 40
    Spanish Toxic Oil Syndrome and, 40
    substances inducing, 40
Azathioprine, immunosuppression and, 6,35,51
Azidothymidine (AZT), 50
B cells
    humoral immunity and 18-19
    quantitation of as a measure of immunotoxicity, 28
    role in antibody production of, 4, 14, 18-19
    suppression by glucocorticosteroids on, 35
    test to assess antibody production capability of, 28
    test to assess mitogen response of, 29
Barth v. Firestone Tire and Rubber Co., 74
Benzene, 6,36,57
Benzidine, 51
Benzo(a)pyrene, 51
Benzo(c)pyrene, 51
Benzothionium chloride, 52
Benzyl-p-chlorophenol, 52
o-benzyl-p-chlorophenol, 51
Buehler test, 30
t-butylhydroquinone, 51
Cadmium, immunosuppression and, 7,38
Cadmium chloride, 51
California legislation related to MCS, 9
workers’ compensation, 72
Cuptafol, 55
Carcinogens historical interest in, 3
Cell-mediated immunity description of, 5, 19, 23
immunotoxicological tests for, 5, 27, 29
importance to normal immune function of, 19-20
occupational dermatoses and, 38
potential adverse consequences due to, 19-20
see also Allergy; Contact sensitivity; Delayed-type hypersensitivity
Cells, immune system, 14-17
Cellularity, as a test for immune pathology, 28
Center for Biologics Evaluation and Research (CBER)–FDA, 53
Center for Drug Evaluation and Research (CDER) – FDA, 53, 56
Center for Environmental Health and Injury Control – CDC, 53
Center for Food Safety and Nutrition (CFSAN) – FDA, 52-53
Centers for Disease Control (CDC), research in immunotoxicology by, 8, 53
Chloral hydrate, 32
Chlordimeform, 34
4-chloro-o-phenylenediamine, 51, 52
Cigarette smoke as a confounding factor in immunotoxicity assessment, 22
immunosuppressive potential of, 7, 37
Clean Air Act (CAA), 8, 37, 52, 54, 56-57
Clean Water Act (CWA), 54, 56, 57-58
Cobalt, 55
Cobaltous sulfate, 54
Community Right-to-Know, 8, 61-62, 63
Complement activation, 14
Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), 54, 56, 60, 62
Consumer Product Safety Act (CPSA), 54, 60-61
Consumer Product Safety Commission (CPSC), research or regulation by, 8, 60-61
Contact sensitivity cosmetics and regulation by FDA of substances causing, 55-56
description of, 19
EPA research in, 52
substances causing, 38
see also Cell-mediated immunity; Delayed-type hypersensitivity; Hypersensitivity
Cosmetics hypersensitivity and, 8, 21, 38
regulation of, 56
Crotonaldehyde, 52
Cyclophosphamide, immunosuppression and, 6, 35, 51
Cyclosporin A, immunosuppression and, 6, 36, 56
Cytokines, 4, 16
Cytotoxic T lymphocyte (CTL) assay, 29
Dayron Corporation v. Morehead, 72
Definitions. See Terminology
Delayed-type hypersensitivity (DTH) description of, 19
EPA requirements to assess biochemical pesticides for, 58-59
substances inducing, 38-39
test to measure, 29
see also Cell-mediated immunity; Contact sensitivity; Hypersensitivity
Department of Agriculture, research or regulation by, 8, 53
Department of Defense, research or regulation by, 8, 53
Department of Health and Human Services, research by, 8, 49
Department of Labor, research or regulation by, 8
2,4-diaminotoluene, 51, 52
Dichloroethane, 32
Dideoxyadenosine, 51
Diethylstilbestrol (DES), 34, 51
Diethylnitrosamine (DMN), 32
Dinitrofluorobenzene, 52
Dioxin Department of Defense study of, 53
immunosuppression and, 7, 32, 36-37
see also TCDD
Diphenylhydantoin, 51
Disability, income replacement for immunotoxicity-related, 69-76
Draize test, 30
Drugs
  autoimmunity and, 40
  hypersensitivity and, 8,38,39
  immunotoxic effects of illegal, 35
  immunosuppression and, 6,39,41
  regulation of, 55-56
  see also Therapeutic drugs
Elam v. Alcolac, 73-74
Emergency Planning and Community Right-to-Know Act (EPCRA), 61-62
Environmental Protection Agency (EPA)
  community right-to-know and, 8,61-62
  coordination about TRI with NLM, 62
  funding of study on multiple chemical sensitivity by, 9
  immunotoxicity testing of biochemical pest control agents and, 58
  regulation by, 56-60
  regulation of oxidant gases based on health effects other than immunotoxicity by, 37
  research in immunotoxicology by, 8,52,63
  role in NTP of, 49
  tier testing and, 52,58-59
Epidemiology
  difficulties in obtaining human immunotoxicity data, 5-6,31-32
  studies of autoimmunity in humans, 5-6, 40
  studies of hypersensitivity in humans, 5-6,31-32
  studies of immunosuppression in humans, 5-6,31-32
Estradiol benzoate, 32
Ethyl carbamate, 51
Ethylene dibromide, 51
Ethylene thiourea, 52
Federal Hazardous Substances Act (FHSA), 54,60-61
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 54,56,58-59
Florida, workers’ compensation, 72
Food and Drug Administration (FDA)
  regulation by, 55-56
  research in immunotoxicology by, 8,52-53,63
  restriction of sulfites by, 8,55,63
role in NTP of, 49
  view on tier testing, 31,53
Food, Drug, and Cosmetic Act (FDCA), 55
Foods, regulation of, 55
Formaldehyde, 37,39,51
Freund’s complete adjuvant test, 30
Funding
  levels for immunotoxicological research by CDC, 53
  levels for immunotoxicological research by EPA, 52
  levels for immunotoxicological research by NIEHS, 53
  levels for immunotoxicological research by NIH, 53
  levels for immunotoxicological research by NIOSH, 53
  levels for immunotoxicological research by NTP, 51
Gallium arsenide, 51
Genetics
  role in autoimmunity, 8,40
  role in evaluating immunotoxicity of populations, 22
Ginseng, 51
Glucocorticosteroids, immunosuppression and, 35
Glutaraldehyde, 52
Grayson v. Gulf Oil Company, 71-72
Halogenated aromatic hydrocarbon (HAH)
  immunosuppression and, 6,36-37
  see also Polybrominated biphenyls; Polychlorinated biphenyl; Dioxin
Hazardous Substances Data Bank (HSDB) –NLM, 62
Hematology, as a test for immune pathology, 28
Hexachlorobenzo-p-dioxin, 51
Higgens v. Aerojet-General Corp., 74-75
Histology, as a test for immune pathology, 28
Host resistance, immunotoxicological tests for, 5,30,50, 52
Human leukocyte antigen (HLA), 22
humoral immunity
  description of, 5,18-19,23
  immunotoxicological tests for, 5,27,28-29
  importance to normal immune function of, 18-19
  potential adverse consequences due to, 19
  see also Allergy; Antibody; Hypersensitivity
Hypersensitivity
  definition, 4
  EPA efforts in methods development for lung, 52
epidemiologic studies of humans for, 6
genetic component of, 22,23
immunotoxicity and, 19-20
immunotoxicological tests for, 5,30-31
pesticides and, 8,39
respiratory disorders and, 38-39
substances causing contact sensitivity and skin disorders, 38
substances tested by NTP for, 52
see also Allergy; Contact sensitivity; Delayed-type hypersensitivity; Immediate-type hypersensitivity

Immediate-type hypersensitivity
allergy and, 19
potential adverse consequences due to, 19
see also Allergy; humoral immunity; Hypersensitivity

Immune suppression. See Immunosuppression

Immune system, 13
cell surface receptors of, 14, 16
cells of, 4, 14-17
organs of, 4, 16-17
reserve capacity of, 5,40
responses of, 4, 17-20
tests to analyze effects of substances on 5,27-31

Immunity. See Acquired immunity; Cell-mediated immunity; humoral immunity; Nonspecific immunity

Immunoglobulin. See Antibody

Immunosuppression
definition, 3-4
halogenated aromatic hydrocarbons and, 36-37
immunotoxicity and, 20
indoor air pollutants and, 37
lack of data on human studies, 34
metals and, 37-38
oxidant gases and, 37
pesticides and, 6,36
polycyclic aromatic hydrocarbons and, 7,37
substances tested by NTP for, 51
tests for, 5
therapeutic drugs and, 6,35-36

immunotoxicant
elements of substances that are, 6-8,35-40
OTA definition of, 4,20
populations at risk to effects of, 22-23
see also immunotoxicity

immunotoxicity
challenges in studying, 5,20-23,32-35,40-41
difficulties in proving claims for, 75-76
disability and, 69-76
epidemiologic evaluation of, 31-32
existing data on, 5,35-40
terminology used in OTA background paper, 3-4, 20-21
tests for, 27-31
tort claims and, 73-75
workers’ compensation and, 71-72
see also immunotoxicant

Indomethacin, 51
Indoor air pollutants, 21,37
Inhalants
EPA development of methods to assess, 52
hypersensitivity induced by, 8

Innate immunity. See Nonspecific immunity

Interferon-alpha, 51
Isocyanates, hypersensitivity and, 8
Isobutyaldehyde, 52
Isophorone diisocyanate, 52,55
Jewelry, hypersensitivity to, 8,38
Kyles v. Workers’ Compensation Appeals Board, 72
Lead, 7,37,57
Lithium carbonate, 51
Lowe v. Norfolk & Western Railway Company, 75
Lymphocytes. See B cells; T cells; Natural killer cells
Lymphoid organs. See Organs

Macrophages
cell-mediated immunity and, 19
humoral immunity and, 18
nonspecific immunity and, 17
role in immune responsiveness of, 4, 13, 16, 18
test to assess activity of, 29,30
test to assess functional capability of in antibody production, 28

Maryland, study related to environmental illness and multiple chemical sensitivity, 9

Material safety data sheets, 61,62
2-mercaptobenzothiazole, 52
Mercury, 7,38,57

Metals
immunosuppression and, 7,37
role in autoimmune processes, 8
role in hypersensitivity, 8
see also Cadmium; Lead; Mercury; Nickel; Organotins

Methyl carbamate, 51
Methyl isocyanate, 50,51
Michigan, polybrominated biphenyl exposure case in, 33
Mine Safety and Health Act, 54, 61
Mine Safety and Health Administration (MSHA), research or regulation by, 8, 61
Mixed leukocyte response (MLR), 29
Moore v. Polish Power, Inc., 74
Mouse ear swelling test (MEST), 30-31
Multiple chemical sensitivity, 9, 73
Murine local lymph node assay, 30-31
NK cells. See Natural killer cells
National Academy of Sciences
meeting on human exposure data sponsored by, 32
study of multiple chemical sensitivity by, 9
National Ambient Air Quality Standards (NAAQS), 52, 57
National Cancer Institute (NCI), 49
National Center for Toxicological Research (NCTR) – FDA, 49
National Commission on State Workmen’s Compensation Laws, 72
National Institute for Occupational Safety and Health (NIOSH), 49
National Institute of Allergy and Infectious Diseases, 53
National Institute of Environmental Health Sciences (NIEHS), 49, 53
National Institutes of Health (NIH), research in immunotoxicology by, 8, 49, 53
National Library of Medicine (NLM), 9, 62-63
National Toxicology Program (NTP)
agencies comprising, 49
funding for immunotoxicological research by, 51, 63
objectives of, 49
research in immunotoxicology by, 8, 49-52
substances tested for hypersensitivity by, 52
substances tested for immunosuppression by, 51
testing approach developed by, 8, 49-52
Natural killer cells
cell-mediated immunity and, 19
nonspecific immunity and, 17
role in immune responsiveness of, 4, 17
test to assess activity of, 29, 30
New Jersey, study related to environmental illness and multiple chemical sensitivity, 9
Nickel
hypersensitivity and, 8, 38
immunosuppression and, 37-38
Nickel chloride, 38
Nickel sulfate, 51
Nitrobenzene, 51
Nitrofurazone, 51
Nitrogen dioxide, 7, 37, 59
n-nitrosodimethylamine, 51
m-nitrotoluene, 51
p-nitrotoluene, 51
Nitrophenylpentadien, 50, 52
Nonspecific immunity
description of, 4, 17
immunotoxicological tests for, 5, 27, 29-30, 50
role of NK cells in, 17
tests for host resistance as a measure of, 30
Ochratoxin A, 51
Occupational Safety and Health Act (OSH Act), 54
Occupational Safety and Health Administration (OSHA)
regulation by, 8, 54, 63
role in NTP of, 49
substances regulated as sensitizers by, 8, 54-55
worker right-to-know and, 8, 61, 63
workers’ compensation and, 70-71
Office of Health Research (OHR) – EPA, 52
Office of Pesticide Programs (OPP) – EPA, 52, 58-59
Office of Technology Assessment (OTA)
evaluation of environmental noncancer health risks by, 3
organization of report by, 3
previous studies on regulation of toxic substances by, 49
Office of Toxic Substances (OTS) – EPA, 52
Oleic acid diethanolamine, 52
Organotins, 7, 38
Organs
immunotoxicity testing of, 28
of the immune system, 4, 17
Oxidant gases, 37. See also Immunosuppression; Nitrogen dioxide; Ozone
Oxymetholone, 51
Ozone, immunosuppression and, 7, 37, 57
Pathology, immunotoxicological tests for, 5, 28
Penicillin, hypersensitivity and, 8, 39
Pentachlorophenol, 51
Pentamidine isethionate, 51
Pesticides
  EPA testing guidelines for immunotoxicity of, 8, 58-59
  hypersensitivity and, 8, 39
  immunosuppression and, 7, 38
Pharmaceuticals. See Drugs
Phenothiazine, 55
Phenyl glycidyl ether, 55
1-phenyl-5-vinyl-2-imidazolidine-thione (PVIZT), 40
o-phenylphenol, 51
Phorbol myristate acetate, 51
Picric acid, 55
Plaque forming cells (PFC), test to assess, 28
Polybrominated biphenyls (PBBs)
  immunosuppression and, 6, 32, 36
  Michigan exposure case, 33
Polychlorinated biphenyl (PCB)
  immunosuppression and, 6, 32, 36
  regulation by EPA under CWA of, 58
  regulation by FDA of, 55
  Taiwan exposure case, 34
Polycyclic aromatic hydrocarbons (PAH), immunosuppression and, 7, 37
Polydimethylsiloxane fluid, 52
Prednisolone, immunosuppression and, 6, 35
Registry of Toxic Effects of Chemical Substances (RTECS)–NLM, 62
Regulation
  by OSHA of substances as sensitizers, 54-55
  major Federal laws controlling toxic substances, 54-61
  of sulfites based on immunotoxic criteria, 8, 55
  of Yellow Dye No. 5 based on immunotoxic criteria, 55
Research
  Federal agencies involved in, 8, 49-54
  interest in Federal interagency coordination committee, 54
  need for integration of immunology and toxicology, 35
  see also Funding
Resource Conservation and Recovery Act (RCRA), 56, 60
Respiratory disorders and hypersensitivity, 7-8, 38-39
Ribavirin, 51
Safe Drinking Water Act (SDWA), 56, 58
Selenium, immunosuppression and, 37-38
Senate Committee on Environment and Public Works, Subcommittee on Toxic Substances, Environmental Oversight, Research and Development interest in noncancer health risks by, 3
request for this OTA background paper by, 3
Silicone, 50, 51
Social Security Administration (SSA), 69
Social Security Disability Income (SSDI), immune system injury and, 69
South Carolina, workers’ compensation and immune system injury, 71-72
Spain, toxic oil exposure case in, 40
Stiles v. Sudstrand, 75
Subtilisins, 55
Sulfites, role in hypersensitivity and restriction by FDA of, 8, 55, 63
Supplemental Security Income (SSI), 69
Suppression of immune responsiveness. See Immunosuppression
T cells
  cell-mediated immunity and, 19-20
  humoral immunity and, 18-19
  mixed lymphocyte response as a measure of, 29
  quantitation of as a measure of immunotoxicity, 28
  role in immune responsiveness, 4, 15-16, 18, 19
  suppression by cyclosporin A on, 36
  suppression by glucocorticosteroids on, 35
  test to assess cytotoxic, 29
  test to assess functional capability of antibody production, 28
  test to assess host resistance activity of, 30
  test to assess mitogen response of, 29
Taiwan, polychlorinated biphenyl exposure case in, 34
Terminology, 3-4
Testing
  challenges and difficulties of, 5-6, 32-35
  methods of, 27-31
Tests
  for cell-mediated immunity, 29
  for host resistance, 30
  for humoral immunity, 28-29
  for nonspecific immunity, 29-30
  for pathology, 28
for potential to induce hypersensitivity, 30-31
selection of, 31
see also Testing; Tier testing
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 36, 51
See also Dioxin
Tetraethyl lead, 51
Tetrahydrocannabinol, 51
Therapeutic drugs. See Drugs
4,4-thiobis (6-t-butyl-m-cresol), 51
Tier testing
EPA approach for biochemical pesticides and, 58-59
EPA efforts to develop, 52,63
FDA perspective on appropriateness of, 31
for possible immunotoxicants, 31
interest in developing for hypersensitivity assessment, 31
NTP approach to, 49-52
Toluene, 51
Toluene-2,3-diisocyanate (TDI)
hypersensitivity and, 39
regulation by OSHA as sensitizer, 39,55
Tort law
congressional interest in, 75
description of, 72-73
difficulties in proving immune system injury under, 75-76
immune system injury and, 73-75
Toxic Release Inventory (TRI) – NLM, 62
Toxic Substances Control Act (TSCA), 54,56,59-60
Toxic torts. See Tort law
Toxicology, general principles of, 7,21-23
Toxicology Data Network (TOXNET) – NLM, 62
TOXLINE-NLM, 62-63
Tributyltin oxide, 52
Triethanolamine, 52
Tris (2,3-dichloropropyl) phosphate, 51
Vanadium pentoxide, 51
Vinyl chloride, 57
4-vinyl-l-cyclohexene diepoxide, 51
White cells, 4, 15
Wisconsin, workers’ compensation and, 70
Woodrow Sterling et al. v. Velsicol Chemical Corp., 73
Worker Right-to-Know, 8,61,63
Workers’ compensation
congressional interest in, 72
description of, 69-71
difficulties in proving immune system injury under, 75-76
immune system injury and, 71-72
OSHA and, 70-71
Xylenesulfonic acid, 52
Yellow Dye No. 5,55,63
Zirconium, hypersensitivity and, 38
Other Related OTA Reports

- **Neurotoxicity: Identifying and Controlling Poisons of the Nervous System--Special Report.** Describes the scope of the public health threat posed by neurotoxic substances; Federal research, testing, monitoring, and regulatory programs to address it; and the economic considerations associated with testing and regulatory programs. BA-436, 4/90; 350 p.
  
  GPO stock #052-003-01184-1; $15.00 per copy

- **Summary—Neurotoxicity: Identifying and Controlling Poisons of the Nervous System.** BA-437, 4/90; 48 p.
  
  GPO stock #052-003-01185-9; $2.25 per copy

- **Genetic Monitoring and Screening in the Workplace.** Examines efficacy, accuracy, and cost of technologies used by employers for genetic screening and monitoring; and the legal and ethical issues pertinent to employer testing. BA-455, 10/90; 270p.
  
  Free summary available from OTA.
  
  GPO stock #052-003-01217-l; $12.00 per copy
  
  NTIS order #PB 91-105 940/AS

- **Identifying and Regulating Carcinogens (BP-H-42)**
  
  NTIS order #PB 88-136999

- **Preventing Illness and Injury in the Workplace (H-256)**
  
  NTIS order #PB 86-115 334/AS

- **Assessment of Technologies for Determining Cancer Risks From the Environment (H-138)**
  
  NTIS order #PB 81-235400

- **Catching Our Breath: Next Steps for Reducing Urban Ozone.** Focuses on the health-based air quality standards for ozone; addresses the problem of regional oxidants; evaluates the cost-effectiveness of controlling various sources of hydrocarbon emissions for lowering ozone levels. 0-412, 7/89; 252 p.
  
  GPO stock #052-003-01158-l; $10.00 per copy
  
  NTIS order #PB 90-130 451/AS

- **Superfund Strategy.** Examines future Superfund needs and how permanent cleanups can be accomplished in a cost-effective manner for diverse types of sites; describes the interactions among many components of the complex Super-fund system; and analyzes the consequences of pursuing different strategies for implementing the program. ITE-252, 4/85; 292 p.
  
  Free summary available from OTA.
  
  GPO stock #052-003-00994-3; $10.00 per copy
  
  NTIS order #PB 86-120 425/AS

- **Protecting the Nation’s Groundwater From Contamination: Volume I (O-233)**
  
  NTIS order #PB 85-154 201/AS

- **Acid Rain and Transported Air Pollutants: Implications for Public Policy.** Characterizes the potential benefits of acting now to abate long-range transported air pollution and the potential costs of premature action. 0-204, 6/84; 324p.
  
  NTIS order #PB 84-222 967/AS

- **MEDLARS and Health Information Policy (TM-H-11)**
  
  NTIS order #PB 83-168658

**NOTE:** Reports are available from the U.S. Government Printing Office, Superintendent of Documents, Washington, DC 20402-9325, (202) 783-3238; and/or the National Technical Information Service, 5285 Port Royal Road, Springfield, VA 22161-0001, (703) 487-4650.